HIV-associated Hodgkin Lymphoma Clinical Trial
Official title:
A Prospective Multicenter Study on HIV-associated Hodgkin Lymphoma
Standard therapy for HIV-related Hodgkin lymphoma (HIV-HL) has not been defined. This trial
was initiated to investigate a risk adapted treatment strategy in patients (pts) with HIV-HL
as established in HIV-negative patients with HL.
Treatment schedule:
- Early stage favorable Hodgkin Lymphoma (HL): 2 cycles of doxorubicin, bleomycin,
vinblastine, and dacarbazine (ABVD) plus 30 Gy involved field (IF) radiation
- Early stage unfavorable HL: 4 cycles of bleomycin, etoposide, doxorubicin,
cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPP)-baseline or 4
cycles of ABVD plus 30 Gy IF radiation
- Advanced HL: 8 cycles of BEACOPP-baseline. BEACOPP should be replaced by ABVD in pts
with far advanced HIV-infection. After the completion of chemotherapy sites of initial
bulky disease (those at least 5 cm in diameter) and residual tumor larger than 2.5 cm
in diameter receive 30 Gy of irradiation.
- Primary outcome measure: tolerability, treatment-related mortality
- Secondary outcome measure: complete remission rate, progression-free survival (PFS),
overall survival (OS).
n/a
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00112593 -
Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer
|
N/A | |
| Completed |
NCT02298257 -
A Pilot Trial of AVD and Brentuximab Vedotin (SGN-35) in the Treatment of Stage III-IV HIV-associated Hodgkin Lymphoma
|
Phase 2 | |
| Completed |
NCT01158274 -
RO4929097 and Capecitabine in Treating Patients With Refractory Solid Tumors
|
Phase 1 | |
| Withdrawn |
NCT01769911 -
Genetically Modified Peripheral Blood Stem Cell Transplant in Treating Patients With HIV-Associated Non-Hodgkin or Hodgkin Lymphoma
|
N/A | |
| Completed |
NCT00890747 -
Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy
|
Phase 1 | |
| Completed |
NCT00005811 -
Topotecan Hydrochloride in Treating Children With Meningeal Cancer That Has Not Responded to Previous Treatment
|
Phase 2 |